0001104659-20-021982.txt : 20200214 0001104659-20-021982.hdr.sgml : 20200214 20200214170027 ACCESSION NUMBER: 0001104659-20-021982 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20191212 FILED AS OF DATE: 20200214 DATE AS OF CHANGE: 20200214 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Almenoff June Sherie CENTRAL INDEX KEY: 0001492647 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36641 FILM NUMBER: 20621553 MAIL ADDRESS: STREET 1: C/O BRAINSTORM CELL THERAPEUTICS INC. STREET 2: 1325 AVENUE OF AMERICAS 28TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10019 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BRAINSTORM CELL THERAPEUTICS INC. CENTRAL INDEX KEY: 0001137883 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 207273918 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1325 AVENUE OF AMERICAS STREET 2: 28TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10019 BUSINESS PHONE: 201-488-0460 MAIL ADDRESS: STREET 1: 1325 AVENUE OF AMERICAS STREET 2: 28TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10019 FORMER COMPANY: FORMER CONFORMED NAME: BRAINSTORM CELL THERAPEUTICS INC DATE OF NAME CHANGE: 20041122 FORMER COMPANY: FORMER CONFORMED NAME: GOLDEN HAND RESOURCES INC DATE OF NAME CHANGE: 20030827 FORMER COMPANY: FORMER CONFORMED NAME: WIZBANG TECHNOLOGIES INC DATE OF NAME CHANGE: 20010409 4 1 tm205737d2_4.xml OWNERSHIP DOCUMENT X0306 4 2019-12-12 0 0001137883 BRAINSTORM CELL THERAPEUTICS INC. BCLI 0001492647 Almenoff June Sherie C/O BRAINSTORM CELL THERAPEUTICS INC. 1325 AVENUE OF AMERICAS, 28TH FLOOR NEW YORK NY 10019 1 0 0 0 Common Stock 2019-12-12 4 A 0 2000 0 A 2000 D Common Stock 7175 I By Meadowlark Management LLC Shares acquired are shares of restricted stock awarded on December 12, 2019 pursuant to the Brainstorm Cell Therapeutics Inc. Second Amended and Restated Director Compensation Plan. The shares of restricted stock vest in 12 consecutive, equal monthly installments commencing on January 12, 2020 until fully vested on the first anniversary of the date of grant, provided that the reporting person remains a director (and committee member, as applicable) of Brainstorm Cell Therapeutics on each vesting date. The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for the purposes of Section 16 or for any other purpose. /s/ Nathaniel Gaede (pursuant to power of attorney) 2020-02-14